Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2023-05-23T00:00:00.000+10:00
Ongoing

Stellar 002

Stellar 002
Solid tumors

Multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumour activity, and effect of biomarkers of XL092 administered alone, and in combination with Nivolumab (doublet), Nivolumab + Ipilimumab (triplet) and Nivolumab + Relatlimab (triplet) in subjects with advanced solid tumours.

Multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumour activity, and effect of biomarkers of XL092 administered alone, and in combination with Nivolumab (doublet), Nivolumab + Ipilimumab (triplet) and Nivolumab + Relatlimab (triplet) in subjects with advanced solid tumours.

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Solid Tumours - Metastatic

Study Phase

1b

Trial Identifiers

Registration number: NCT05176483.

https://clinicaltrials.gov/study/NCT05176483

GenesisCare Location(s)

North Shore 

North Shore  :::
Principal Investigator(s)

Dr Laurence Krieger

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.